Thursday’s insider activity: Notable buys at Agora and Rapport

Here’s a roundup of the most significant insider buying and selling activity disclosed on Thursday across US public companies.

Top buys

Agora, Inc. (NASDAQ:API) saw its Chief Executive Officer and Director, Zhao Bin, acquire American Depositary Shares totaling $168,304 through indirect holdings over four trading days in October 2026. The purchases were executed between October 19 and October 22, 2026, as part of a Rule 10b5-1 trading plan adopted by YY TZ Limited on June 15, 2026. Over the period, Mr. Zhao, through YY TZ Limited, purchased a total of 38,267 ADSs at prices ranging from $4.3551 to $4.4551 per ADS. One ADS represents four Class A Ordinary Shares of Agora, Inc. The insider purchases come as Agora trades at $4.39, with the stock showing momentum after gaining nearly 23% over the past six months. According to InvestingPro analysis, the company appears undervalued at current levels and holds more cash than debt on its balance sheet.

Rapport Therapeutics, Inc. (NASDAQ:RAPP) experienced significant insider buying from director Paul Steven M., who recently acquired 35,714 shares of the company’s common stock, totaling approximately $974,277. The transactions, which took place on October 22, 2026, saw shares purchased at prices ranging from $26.87 to $27.84, with a weighted average price of $27.28 per share. Following this transaction, Mr. Paul Steven M. indirectly holds 77,380 shares of Rapport Therapeutics common stock through Paul Capital Strategy III Fund LLC. Mr. Paul disclaims beneficial ownership of these shares except to the extent of his pecuniary interest. The insider purchase comes as the stock trades near $26.53, down 27% over the past six months. According to InvestingPro analysis, RAPP appears undervalued at current levels, with analysts maintaining a strong buy consensus and price targets ranging from $50 to $91.

Rapport Therapeutics, Inc. (NASDAQ:RAPP) also saw director John Maraganore acquire shares totaling $248,891 on October 22, 2026, according to a recent SEC filing. The transactions involved the acquisition of 9,411 shares of common stock. One block consisted of 8,239 shares, acquired at a weighted average price of $26.3799 per share, with individual transaction prices ranging from $25.81 to $26.73. A separate purchase involved 1,172 shares, acquired at a weighted average price of $26.9173 per share, with individual transaction prices ranging from $26.81 to $26.98. The purchases come as the stock trades at $26.53, down nearly 4% over the past week. According to InvestingPro data, the stock’s RSI suggests it’s in oversold territory.

Corebridge Financial, Inc. (NASDAQ:CRBG) received a substantial vote of confidence from Nippon Life Insurance Co., a 10% owner and director, who recently purchased $6.77 million worth of the company’s common stock. The transaction, which occurred on October 20, 2026, involved the acquisition of 193,357 shares. The shares were bought at prices ranging from $34.51 to $35.34, with a weighted average price of $35.0106 per share. These purchases were executed under a Rule 10b5-1 trading plan that Nippon Life Insurance Co. adopted on August 7, 2026. The timing of the purchase is notable, as the stock is currently trading near its 52-week high of $35.64, following a strong 36% gain over the past six months.

BNY Mellon Strategic Municipals, Inc. (NYSE:LEO) saw significant shareholder and director Saba Capital Management, L.P. acquire 45,831 shares of the company’s common stock on October 21, 2026. The transaction totaled $262,611, with shares purchased at a price of $5.73 each. Following this acquisition, Saba Capital Management, L.P. indirectly holds 6,482,189 shares of BNY Mellon Strategic Municipals, Inc. The securities are held by various funds and accounts for which Saba Capital Management, L.P. acts as the investment manager. Boaz R. Weinstein serves as the managing member of Saba Capital Management GP, LLC, which is the general partner of Saba Capital Management, L.P.

Top sells

United Therapeutics Corp (NASDAQ:UTHR) saw its Chairperson and Chief Executive Officer, Martine A. Rothblatt, sell shares totaling approximately $5.32 million on October 21, 2026. The transactions were executed as part of a pre-arranged 10b5-1 trading plan. Ms. Rothblatt disposed of a total of 9,500 shares of common stock at prices ranging from $552.52 to $566.43 per share, amounting to a total value of $5,320,680. The timing of the sale comes as United Therapeutics stock trades near its 52-week high of $609.35, with shares currently at $584.79. The company has delivered a strong 37% return over the past year, though InvestingPro analysis suggests the stock appears overvalued relative to its Fair Value, placing it among companies on the Most Overvalued list.

Innsuites Hospitality Trust (IHT) experienced a major transaction as President and Chief Executive Officer and Chairman James F. Wirth recently sold a significant number of shares in the company. On October 20, 2026, Mr. Wirth disposed of 43,111 shares of Innsuites Hospitality REIT. The shares were sold at a price of $46,654.38 per share, totaling approximately $2,011,316,976. The deemed execution date for this transaction was October 22, 2026. The sale comes as the stock has declined 22.76% over the past year, currently trading at $1.11 with a market capitalization of $14.83 million.

Arista Networks (NASDAQ:ANET) saw its President and Chief Technology Officer, Kenneth Duda, sell shares totaling approximately $7.84 million on October 20, 2026. The transactions also included the exercise of stock options. All reported transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which Mr. Duda established on March 11, 2026. Mr. Duda directly disposed of 17,333 shares of Arista Networks common stock, generating approximately $3.14 million. These shares were sold at weighted average prices ranging from $177.9108 to $182.7925 per share. The insider sales come as Arista’s stock has delivered a 30.6% return year-to-date, though shares recently declined 7.8% over the past week to $171.07. According to InvestingPro analysis, the stock currently appears slightly overvalued relative to its Fair Value, placing it among companies on the most overvalued list.

LINDBLAD EXPEDITIONS HOLDINGS, INC. (NASDAQ:LIND) saw director and 10% owner Sven-Olof Lindblad sell a total of 240,965 shares of common stock for approximately $8,638,476 over several transactions between October 20 and October 22, 2026. The sales were executed under a pre-arranged Rule 10b5-1 trading plan. The shares were sold at prices ranging from $33.71 to $36.71 per share. On October 20, Mr. Lindblad disposed of 8,200 shares, 50,414 shares, and 16,931 shares. Further sales on October 21 included 56,814 shares and 40,656 shares. The final reported sales on October 22 comprised 60,497 shares and 7,477 shares. The timing coincides with the stock trading near its 52-week high of $36.97, following a remarkable 180% gain over the past year. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value, placing it among the most overvalued stocks tracked by the platform.

Braze, Inc. (NASDAQ:BRZE) experienced significant insider selling as Chief Technology Officer Jonathan Hyman recently sold a total of 295,000 shares of the company’s Class A Common Stock for an aggregate value of $13,219,450. The transactions occurred between October 15 and October 20, 2026, and were executed pursuant to a Rule 10b5-1 trading plan adopted on April 14, 2026. On October 15, 2026, Mr. Hyman disposed of 10,000 shares at a weighted average price of $30.04 per share, with individual transactions ranging from $30.00 to $30.10. A subsequent sale on October 20, 2026, involved 285,000 shares at a weighted average price of $45.33 per share, with individual transaction prices between $45.26 and $45.45. The timing coincides with remarkable stock momentum, as shares surged 51% in just one week and now trade at $45.86, nearly touching the 52-week high of $45.95. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value.

Monitoring insider buying and selling activity can provide valuable insights into how company executives and major shareholders view their stock’s prospects. While insider purchases may signal confidence in a company’s future performance, and sales might suggest concerns or simply portfolio rebalancing, these transactions should be considered alongside other fundamental and technical factors when making investment decisions. Insider trades executed through pre-arranged 10b5-1 trading plans are typically scheduled in advance and may be less indicative of near-term sentiment than discretionary transactions.